Next » | All Messages |  PKI Message Board Home | recommend post |  Ignore Poster

PKI News Richard F. Begley Named Vice President and General Manager of PerkinElmer Analytical Sciences

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced that Richard F. Begley, Ph.D., has joined the Company as vice president and general manager of its Analytical Sciences business. In this position, he will develop and lead the growth strategy globally for the organization’s entire portfolio of analytical instrumentation which includes chromatography, atomic and molecular spectroscopy, thermal analysis and laboratory information management systems (LIMS).

Begley joins PerkinElmer from Ensemble Discovery, an innovator in DNA programmed chemistry used in drug discovery, where he held the positions of president and chief executive officer. Prior to this, he served as CEO and president of 454 Life Sciences, a developer of instruments, consumables, software and services for rapidly sequencing the human genome. Begley held senior management positions with Agilent/Hewlett-Packard, including director of manufacturing, general manager of its Chemical Solutions and Mass Spectrometry units, and head of Worldwide R&D for the Chemical Analysis Group. In addition, he has served with Schlumberger and Los Alamos National Laboratories.

“Dick has both deep scientific and business expertise in the life and analytical sciences industry as well as a proven track record of creating innovative new product offerings that anticipate and respond to customer needs,” said Robert F. Friel, president, PerkinElmer Life and Analytical Sciences. “He will spearhead our analytical solutions to help scientists advance the pace and precision of their research and testing.”

“I am excited to take on this leadership role for PerkinElmer and look forward to further growing our leading position in analytical sciences through a continued focus on innovation and comprehensive support of our customers,” said Begley.

Begley holds a Ph.D. in Applied Physics, a master’s degree in Applied Physics and an Executive MBA, all from Stanford University. He also holds a bachelor’s degree in Physics from Fordham University.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information

Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.